Posts Tagged ‘ADA Scientific Sessions’

Semaglutide at ADA2024: Old News or Gaining Momentum?

June 25, 2024 — It’s over. The 84th Scientific Sessions of the American Diabetes Association came to an end yesterday and for anyone interested in obesity, it has given us a lot to absorb. After four days with a steady stream of new information about drugs like the GLP-1 agonists that regulate appetite and adiposity, we are left wondering. […]

ADA2024: How Big Is the Problem with Scale for Obesity Care?

June 24, 2024 — One thing is plain to us in the huge showing of interest in obesity at the American Diabetes Association Scientific Sessions (ADA2024). The scale of opportunity is large because the unmet medical need is great. And yet we face a tremendous problem of scale for coping with the need for obesity care. We have problems […]

A First and a Burst of Evidence for Sleep Apnea and Obesity

June 22, 2024 — We like to celebrate firsts. And yesterday, we got one to celebrate in the first ever drug treatment shown to be effective for sleep apnea – the obesity medicine called tirzepatide. In presenting this new research at the American Diabetes Association Scientific Sessions yesterday, Atul Malhotra reminded us, “sleep is an important part of cardiometabolic […]

ADA2023: A Golden Age of Obesity Medicine?

June 26, 2023 — “We may be on the cusp of an era of astonishing innovation – the limits of which aren’t even clear yet,” writes David Wallace-Wells in the New York Times. Among other breakthroughs, he cites the transformation in care that semaglutide and tirzepatide are bringing for the most prevalent chronic disease in the world – obesity. […]

ADA2023: A Frustrating Quest for Healthy Food

June 25, 2023 — We take it as a given – we want to eat healthy. Since 2016, FDA has been working on developing an updated definition for the meaning of “healthy” if a food seller wants to say that about one of its products. The agency is still struggling with this question today. So we were glad to […]

ADA2023 in San Diego: Watching Tides Roll In

June 24, 2023 — Suddenly at the ADA2023 meeting in San Diego, it seems the tides are rolling in to promise more options than ever before for treating obesity. By tides we mean all those drugs targeting the GLP-1 receptors. GLP-1 is shorthand for glucagon-like peptide 1. Most, but not all of these drugs making a splash in San […]

Regarding a Person as More Than a Diagnosis

June 7, 2022 — Just about any medical diagnosis can be a bit dehumanizing. Even more so when a medical professional takes it a step further and explicitly labels a person with their diagnosis. For most diseases, health professionals have long understood that labeling people in this way – as an “epileptic,” for example – is bad form. But […]